Deutsche Bank
XTLB

Deutsche Bank’s XTL Biopharmaceuticals XTLB Stock Holding History

Deutsche Bank’s Portfolio XTLB Stock Details XTLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-325
Closed -$2K – 5474
2018
Q4 		$2K Buy
+325
New +$3.05K ﹤0.01% 5072

Other funds holding XTLB

NC
Noked Capital Tel Aviv, Israel $946K AUM 17.1% 1-Year Est. Return
NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank's XTLB Position: Q1 2019 in Review

Deutsche Bank sold out of XTL Biopharmaceuticals (XTLB) in Q1 2019, closing a stake of 325 shares — an estimated $2K sold.

Deutsche Bank first reported a position in XTLB in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 5 funds tracked by Wall St. Rank hold XTLB as of Q1 2019.

  • Deutsche Bank reported no remaining XTL Biopharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Deutsche Bank sold 325 XTL Biopharmaceuticals shares in Q1 2019, an estimated $2K.
  • Deutsche Bank first reported a position in XTL Biopharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Deutsche Bank's XTL Biopharmaceuticals position peaked at $2K in Q4 2018.
  • 5 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q1 2019.

Based on Deutsche Bank's 13F filing for Q1 2019, filed 15 May 2019.